FY2025 EPS Estimates for AnaptysBio Lifted by HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of AnaptysBio in a research note issued to investors on Wednesday, November 5th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn ($3.56) per share for the year, up from their prior estimate of ($5.82). HC Wainwright currently has a “Buy” rating and a $59.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q4 2025 earnings at ($1.42) EPS, FY2026 earnings at ($5.87) EPS, FY2027 earnings at ($12.28) EPS, FY2028 earnings at ($4.20) EPS and FY2029 earnings at ($2.13) EPS.

A number of other analysts also recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of AnaptysBio from $55.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wedbush boosted their target price on AnaptysBio from $45.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. UBS Group reaffirmed a “neutral” rating and set a $20.00 price target (up from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. Finally, Wells Fargo & Company lifted their target price on shares of AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and an average target price of $61.30.

AnaptysBio Stock Up 6.1%

Shares of AnaptysBio stock opened at $38.20 on Friday. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $40.96. The company has a market cap of $1.06 billion, a PE ratio of -13.55 and a beta of 0.16. The business has a 50 day moving average of $28.43 and a 200 day moving average of $24.55.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The company had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently modified their holdings of the stock. Rhumbline Advisers increased its position in AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock valued at $574,000 after acquiring an additional 826 shares during the last quarter. US Bancorp DE grew its stake in AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 979 shares in the last quarter. Bessemer Group Inc. increased its stake in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the period. Corton Capital Inc. raised its holdings in shares of AnaptysBio by 12.2% in the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 1,305 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.